Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics, AstraZeneca CAMCAR Team on Dx Testing in Central America and Caribbean

NEW YORK (GenomeWeb) – Cancer Genetics announced today that it has signed an agreement with AstraZeneca CAMCAR, a division of drug giant AstraZeneca, to provide biomarker-based cancer diagnostic testing in Central America and the Caribbean.

The Rutherford, NJ-based molecular diagnostics firm said that the collaboration is expected to include multiple cancers, but it will initially focus on lung cancer. In addition, Cancer Genetics said that it will explore expansion of the relationship with AstraZeneca CAMCAR into additional geographic territories and into select oncology trials.

Financial and other terms of the agreement were not disclosed.

Earlier this year, Cancer Genetics announced an expansion of its agreement with Roche Servicios for the same regions. Under that deal, Cancer Genetics is using Roche's cobas platform to provide molecular diagnostic cancer testing for lung cancer, breast cancer, and lymphoma.